A large real-world study of more than 40,000 patients suggests the drugs may reduce the risk of psoriatic arthritis in people with psoriasis, with benefits emerging within a year and persisting long term.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prevents the onset of psoriatic arthritis in patients with psoriasis, according to a large cohort study.
Researchers used real-world data from the TriNetX network to analyse more than 40,000 matched patients.
They found treatment with GLP-1 RAs was associated with a significantly lower risk of developing psoriatic arthritis compared with non-use, with the protective signal emerging within the first year and persisting over a decade.
Their findings have been published as a brief report in the Journal of the American Academy of Dermatology.
“Psoriatic arthritis (PsA) develops in up to one-third of patients with psoriasis (PsO) and can cause irreversible joint damage and impairment. Obesity and diabetes increase the risk for psoriatic and inflammatory arthritis, highlighting the importance of therapies that target metabolic and inflammatory pathways,” the researchers wrote.
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an increasingly prescribed class of medications for weight loss and diabetes.
“Whether GLP-1 RAs are associated with reduced PsA risk in PsO has not been fully elucidated.”
Drawing on de-identified electronic health records from over 100 million patients, investigators identified adults aged 18 to 90 years with psoriasis and no prior inflammatory arthritis.
Related
Patients receiving at least two prescriptions for GLP-1 RAs were matched 1:1 to non-users based on demographics, comorbidities and psoriasis treatments.
The final cohort included 22,431 GLP-1 RA users and 23,826 controls, with comparable baseline characteristics across groups. The mean age was approximately 55 years, with a predominance of female patients and a majority identifying as white.
Within one year of follow-up, GLP-1 RA use was associated with a 43% reduction in the risk of developing psoriatic arthritis (hazard ratio 0.57; 95% CI 0.50–0.64).
Over 10 years, the benefit remained significant, with a 26% reduction in risk (HR 0.74; 95% CI 0.68–0.80). Similar reductions were observed for broader inflammatory arthritis outcomes.
Subgroup analyses showed consistent risk reduction across patients with type 2 diabetes, obesity and across sexes.
Notably, newer agents such as semaglutide and tirzepatide were associated with an even greater reduction in long-term risk, with a 36% decrease over 10 years (HR 0.64; 95% CI 0.57–0.71).
The findings align with emerging evidence that GLP-1 RAs exert anti-inflammatory effects beyond glycaemic control.
“Experimental data suggest that GLP-1 RAs suppress pro-inflammatory cytokine activity and oxidative stress while improving adiposity and decreasing mechanical stress at entheses,” the researchers wrote.
“Through these complementary mechanisms, GLP-1RAs may enhance current therapies and extend benefit across skin, joint, and cardiometabolic domains.”
The authors note study limitations, including the retrospective design, reliance on diagnostic coding and lack of data on disease severity or treatment adherence. Residual confounding could not be excluded.
Even so, the scale and consistency of the signal strengthen the case for prospective trials to test whether GLP-1 RAs can be deployed as a preventive strategy against psoriatic arthritis in high-risk patients.
“Future prospective studies are needed to clarify the role of GLP-1 RAs in the transition from PsO to PsA,” the researchers concluded.
